Biotech · Cambridge, MA · Founded 2022 · Privately Held (backing)
Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases. Merida Biosciences is based in Cambridge, MA and was founded in 2022. It was valued at $228 million at its early-stage round in Apr 2025, the last priced event on record. It has raised $154 million across 1 recorded round; the latest was a $121 million Series A in Apr 2025.
PMV mark · valuation
$228.0M
Oct 2026
Priced at
its early-stage round
Apr 2025
Total raised
$154.0M
Last round
Series A
Apr 2025
Cap table — not yet on record
Merida Biosciences's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Merida Biosciences with a free account
·Everyone on the team, board and advisors included
·Watch Merida Biosciences: the Monday email on marks, rounds and moves
Where does Merida Biosciences's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Merida Biosciences's 1 recorded funding rounds.
